Dacarbazine for injection

Pharmacology: This product has anti-tumor effects. Since it is a precursor of purine biosynthesis, it can interfere with purine biosynthesis. After entering the body, it demethylates to form monomethyl compounds in liver microsomes, which have direct cytotoxic effects. It mainly acts on the G2 phase. It inhibits the synthesis of purine, RNA and protein, and also affects the synthesis of DNA. Therefore, it is also considered to be an alkylating agent anti-tumor drug.

Ingredients: Dacarbazine. Chemical name: 5-(3,3-dimethyl-1-triazene)-imidazole-4-carboxamide citrate.

Alkaline brown-red solid powder, decomposes when heated, and is unstable when exposed to acid and light.

This product is used to treat malignant melanoma

1. Intravenous injection. 200-400mg/m2 per day, for 5-10 days. To reduce irritation to blood vessels, use 10-15ml of normal saline, dissolve it, and then dilute it with 250ml of 5% glucose solution and drip it. It takes more than 30 minutes to drip it. 5-10 days of continuous use is a course of treatment. Generally, it is repeated every 3-6 weeks. For malignant melanoma of the limbs, arterial injection with a nutrient dose can be used. The blood concentration reaches a peak 30 minutes after each intravenous injection, drops to zero within 6 hours, and 30% is excreted in the urine within 0-6 hours. It cannot pass the blood-brain barrier. Single large dose: 650-1450mg/㎡, once every 4-6 weeks. 2. Intravenous drip: 200mg/㎡ each time, once a day, for 5 consecutive days, and repeated every 3-4 weeks. 3 Arterial perfusion: Arterial perfusion: Malignant melanoma located in the limbs can be treated with the same dose of arterial injection.

1. Gastrointestinal reactions: such as loss of appetite, nausea, vomiting, diarrhea, etc., which may be alleviated or disappear after 2 to 8 hours. 2. Bone marrow suppression: It may cause a decrease in white blood cells and platelets, and anemia, which is more obvious at high doses. Generally, a decrease in blood count occurs 2 to 3 weeks after medication, and it may return to normal in the 4th to 5th week. 3. A small number of patients may experience flu-like symptoms, such as general discomfort, fever, and muscle pain, which may occur 7 days after medication and last for 1 to 3 weeks. Facial numbness and hair loss may also occur. 4. Local reactions: Vascular irritation reactions may occur at the injection site. 5. Occasionally, liver and kidney function damage may occur.

1. Patients with chickenpox or herpes zoster are prohibited from using this product. 2. Patients with a history of severe allergies are prohibited from using this product. 3. Pregnant women are prohibited from using this product.

When this product is used in combination with other drugs or radiation that suppress the bone marrow, the dosage of this product should be reduced.

Keep in a dark place, seal tightly, and store at 2-8℃.

0.2g

Shanxi PUDE Pharmaceutical Co., Ltd.

• Founded in:

  1995-09-13

• Address:

  The First Pharmaceutical Park, Datong Economic and Technological Development Zone, Shanxi Province

• Tax NO.:

  91140200602167297K

• Registered Funds:

  138.8 million yuan

• Website:

  Log in to view

• Email:

  Log in to view